Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.58 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 4/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5875508 | 0.99 | MAPK14 (0.59) | MAPK14CSNK1DGSK3BMAPK10MAPK13 | |
| SCHEMBL5875701 | 0.96 | MAPK14 (0.61) | MAPK14CSNK1DGSK3BMAPK13MAPK12 | |
| SCHEMBL5462491 | 0.84 | CSNK1D (0.51) | MAPK14CSNK1DGSK3BMAPK10MAPK13 | |
| SCHEMBL5456838 | 0.83 | CSNK1D (0.51) | MAPK14CSNK1DGSK3BMAPK10MAPK13 | |
| SCHEMBL5452916 | 0.83 | CSNK1D (0.51) | MAPK14CSNK1DGSK3BMAPK10MAPK13 | |
| SCHEMBL5461798 | 0.83 | MAPK14 (0.53) | MAPK14CSNK1DGSK3BMAPK10MAPK13 | |
| SCHEMBL5875691 | 0.82 | MAPK14 (0.61) | MAPK14CSNK1DGSK3BMAPK13MAPK12 | |
| SCHEMBL5875628 | 0.81 | MAPK14 (0.59) | MAPK14CSNK1DGSK3BMAPK13 | |
| SCHEMBL5875632 | 0.81 | MAPK14 (0.59) | MAPK14CSNK1DGSK3BMAPK10MAPK13 | |
| SCHEMBL5890927 | 0.80 | CDK4 (0.49) | MAPK14CSNK1DGSK3BMAPK10MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7034030-B2 | Pyralopyridines, process for their preparation and use as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-25 | — | — | US | claimed |
| US-7109209-B2 | Pyrazolopyridines, process for their preparation and use as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-19 | — | — | US | disclosed |
| US-7034030-B2 | Pyralopyridines, process for their preparation and use as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| US-20060058319-A1 | Pyrazolopyridines, process for their preparation and use as therapeutic compounds | ALBERTI MICHAEL J | 2006-03-16 | — | — | US | disclosed |
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058319-A1 | Pyrazolopyridines, process for their preparation and use as therapeutic compounds | CYP3A5, CYP3A4, CYP3A7 | MAPK14 2256/4885CSNK1D 542/4885GSK3B 2419/4885 |
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | QDPR, DPYD, ENTPD5 | MAPK14 1551/4885CSNK1D 2789/4885GSK3B 3047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.